Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab-Reference-Cited by-同舟云学术

Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab

Published:2021 Issue: Volume:4 Page:100083
ISSN:2589-9090
Container-title:Journal of Translational Autoimmunity
language:en
Short-container-title:Journal of Translational Autoimmunity

Author:

Agresti Nicholas,Lalezari Jacob P.,Amodeo Phillip P.,Mody Kabir,Mosher Steven F.,Seethamraju Harish,Kelly Scott A.,Pourhassan Nader Z.,Sudduth C. David,Bovinet Christopher,ElSharkawi Ahmed E.,Patterson Bruce K.,Stephen Reejis,Sacha Jonah B.,Wu Helen L.,Gross Seth A.,Dhody Kush

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference46 articles.

1. Novel Coronavirus (2019-nCoV): Situation Report 1;World Health Organization,2020

2. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China;Huang;Lancet,2020

3. Of the Treasury,2020

4. Formal guidelines: management of acute respiratory distress syndrome;Papazian;Ann. Intensive Care,2019

5. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression;Zhou;J. Antimicrob. Chemother.,2020

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging trends and therapeutic applications of monoclonal antibodies;Gene;2024-10

2. Non-Conventional Prognostic Markers in Life-Threatening COVID-19 Cases—When Less Is More;Journal of Clinical Medicine;2024-09-11

3. Upregulation of key factors of viral entry of corona‐ and influenza viruses upon TLR3‐signaling in cells from the respiratory tract and clinical treatment options by 1,8‐Cineol;Phytotherapy Research;2024-07-17

4. The Immune Response of OAS1, IRF9, and IFI6 Genes in the Pathogenesis of COVID-19;International Journal of Molecular Sciences;2024-04-24

5. Evaluation of the serum levels of CCL2, CCL3, and IL-29 after first and second administrations of the COVID-19 vaccine (Oxford–AstraZeneca);Immunobiology;2024-03